{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/prescribing-information/emollients/","result":{"pageContext":{"chapter":{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients","depth":2,"htmlHeader":"<!-- begin field 5c6a8241-bc0d-418a-bd6d-5761f532af4b --><h2>Emollients</h2><!-- end field 5c6a8241-bc0d-418a-bd6d-5761f532af4b -->","summary":"","htmlStringContent":"<!-- begin item 57a5e606-db4a-4d37-abf7-bdf8692e0768 --><!-- end item 57a5e606-db4a-4d37-abf7-bdf8692e0768 -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ce3be64b-a968-59e2-b206-5a055de98330","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"90a6d526-b31a-5906-a7c9-205b23bbbd8e","slug":"availability-choice","fullItemName":"Availability and choice","depth":3,"htmlHeader":"<!-- begin field e4fc4577-5739-4a40-892d-bf26b84042c0 --><h3>Availability and choice</h3><!-- end field e4fc4577-5739-4a40-892d-bf26b84042c0 -->","summary":"","htmlStringContent":"<!-- begin item e4142c1e-4159-40a6-aa62-d6b9607d4181 --><!-- begin field 4f4df186-11e9-4921-ae19-f7213292d779 --><h4>Available products</h4><ul><li>There are a large number of emollients available in the UK, including creams, ointments, gels, lotions, sprays, washes, and bath and shower additives, available as non-proprietary and/or proprietary products.<ul><li>For a complete list of all the emollient products available in the UK, see the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"33285e0a-d144-4ee7-bb39-a93100b9dea7\">BNF</a>).</li></ul></li><li>Most emollient products are plain (that is, contain no active ingredients).<ul><li>However, some emollients contain active ingredients:<ul><li>Urea (a keratin softener and hydrating agent), for example Aquadrate<sup>®</sup>, Balneum<sup>®</sup> Plus, Calmurid<sup>®</sup>, E45<sup>®</sup> Itch Relief Cream, and Eucerin<sup>®</sup> Intensive.</li><li>Lauromacrogols (which have local anaesthetic properties, and soothe and relieve itchy skin), for example Balneum<sup>®</sup> Plus and E45<sup>®</sup> Itch Relief Cream.</li><li>Lanolin or lanolin derivatives, for example hydrous ointment, E45<sup>®</sup> cream and lotion, and Oilatum<sup>®</sup> emollient bath additive.</li><li>Antiseptic, for example Dermol<sup>®</sup> preparations (cream, lotion, shower, and bath emollient), Emulsiderm<sup>®</sup> liquid emulsion, and Oilatum Plus<sup>®</sup> bath additive.</li></ul></li><li>Emollients containing active ingredients are not generally recommended because they increase the risk of skin reactions. However, they may be useful in some people.<ul><li>Aqueous cream is generally not recommended because of the high risk of developing skin reactions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">MHRA, 2013</a>].</li></ul></li></ul></li><li>All emollients are available on the NHS, but some are classified as borderline substances and as such their prescriptions should be endorsed with 'ACBS' (Advisory Committee on Borderline Substances). These include Aveeno<sup>®</sup> products (bath oil, cream, and lotion) and E45<sup>®</sup> products (emollient bath oil, emollient wash cream, and lotion).<ul><li>Preparations marked ‘ACBS’ are regarded as drugs when prescribed in accordance with the advice of the ACBS for the clinical conditions listed. See the <a href=\"http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx\" data-hyperlink-id=\"fd1cc450-39fc-4147-805c-a93100b9ded5\">Drug Tariff </a>for more information.</li></ul></li><li>Emollients are also available over-the-counter, although availability may be limited.</li></ul><h4>Choice of products</h4><ul><li>There is no evidence from controlled trials to support the use of one emollient over another [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">van Zuuren, 2017</a>].</li><li>Prescribe an emollient according to the dryness of the skin, and the person's preference and tolerance to treatments.<ul><li>Creams and lotions are preferred for red, inflamed areas of skin because the evaporation of water-based products cools the skin.</li><li>Ointments are preferred for dry skin (that is not inflamed) because they are more effective than creams, however they may be poorly tolerated compared with creams.</li><li>Proprietary products are often preferred to non-proprietary products.</li><li>Several different emollients may be required (for example for different areas of skin, different stages of flare, or for use in different locations).</li></ul></li><li>Where possible, prescribe an emollient with a pump dispenser to minimize the risk of bacterial contamination.<ul><li>For emollients that come in pots, advise that using a clean spoon or spatula (rather than fingers) to remove the emollient helps to minimize contamination.</li></ul></li><li>Emollients containing active ingredients are not generally recommended because they increase the risk of skin reactions, however they may be useful in some people.</li><li>Prescribe emollients to replace soap in people with dry skin requiring treatment.<ul><li>Ointments dissolved in hot water are suitable soap substitutes.</li><li>Bath additives and shower products are an option for people with extensive areas of dry skin.</li><li>If bath emollients are used, it is essential that they do not replace standard emollients.</li></ul></li><li>The effectiveness and acceptability of a particular emollient may vary with time.<ul><li>If the person feels that a particular product has become unsuitable for them (or if they have developed sensitivity to it), prescribe an alternative emollient.</li><li>It may be necessary to try a range of emollients before the person finds the best combination for their skin.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Eichenfield, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 4f4df186-11e9-4921-ae19-f7213292d779 --><!-- end item e4142c1e-4159-40a6-aa62-d6b9607d4181 -->","subChapters":[]},{"id":"cdf7868f-948c-5ed6-89ac-49d68d961539","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d7370e4a-4a77-4bd9-92bf-cbdc00d4cdbb --><h3>Adverse effects</h3><!-- end field d7370e4a-4a77-4bd9-92bf-cbdc00d4cdbb -->","summary":"","htmlStringContent":"<!-- begin item 5d1ae723-82b3-485b-be35-4b2ec6d7f7bb --><!-- begin field 1bff7b84-c8e6-4008-8922-db00dd0a59fa --><ul><li><strong>Emollients are usually well tolerated, and skin reactions are the most common adverse effects.</strong> They are caused by sensitivity of the skin to additives in the emollient, such as perfumes, preservatives, and biological components, such as lanolin.<ul><li>If a skin reaction occurs,<strong> </strong>stop the emollient and use a different one.</li><li>If the person has had previous skin reactions to emollients, consider testing a small quantity on the skin before widespread application.</li><li>If a person has known sensitivity to emollients, prescribe a cream with few additives, or an ointment (ointments do not require preservatives and generally have less excipients), to reduce the chance of a further reaction.</li></ul></li><li>The occlusive effect of ointments can cause folliculitis. If this occurs, stop the ointment, consider switching to a cream, and manage appropriately.</li><li>Paraffin-containing products (for example emulsifying ointment and liquid and white soft paraffin ointment) are highly flammable and should not be used near naked flames.</li><li>Bath emollients can pose a slip hazard.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">MHRA, 2016</a>] </p><!-- end field 1bff7b84-c8e6-4008-8922-db00dd0a59fa --><!-- end item 5d1ae723-82b3-485b-be35-4b2ec6d7f7bb -->","subChapters":[]},{"id":"78536a91-5290-5aca-82af-c742d8004a01","slug":"application","fullItemName":"Application","depth":3,"htmlHeader":"<!-- begin field 4967007c-2b46-4709-80d3-c02da4c4c1a1 --><h3>Application</h3><!-- end field 4967007c-2b46-4709-80d3-c02da4c4c1a1 -->","summary":"","htmlStringContent":"<!-- begin item 9446f635-9143-4459-a7c1-4426d6601716 --><!-- begin field b3877253-e2d1-4145-bb44-13ec56c07c15 --><p><strong>It is essential to provide instructions on the correct use of emollients, with clear demonstrations where appropriate.</strong></p><ul><li>Advise the person to use emollients liberally and frequently, even when their skin appears improved or is clear.<ul><li>It is recommended that 250–500 g of emollient be applied every week.</li><li>The frequency of application will vary depending on the person's skin disease, but for very dry skin, application of an emollient every 2–3 hours should be considered normal.</li><li>To help frequent application, the person should consider keeping separate packs of emollients at work or school.</li></ul></li><li>Advise on the appropriate use of emollients.<ul><li>Advise the person to use emollients during or after washing. The skin should be gently dried and the emollient applied while the skin is still moist.</li><li>Smooth the emollient gently into the skin along the line of hair growth, rather than rubbing them in.</li><li>It may be more convenient to use better tolerated products (such as creams and lotions) during the day, and ointments (which are usually less well tolerated) at night.</li><li>If an active topical treatment is used, such as corticosteroids, the person should wait about 15–30 mins if possible after application of an emollient, before applying the active treatment.</li><li>Emollient products should not be shared with other people as they may become contaminated with pathogens.<ul><li>Pump dispensers minimize the risk of contamination.</li><li>For emollients that come in pots, using a clean spoon or spatula (rather than fingers) to remove the emollient helps to minimize the risk of contamination.</li></ul></li></ul></li><li>Advise the person:<ul><li>To avoid the use of soaps, detergents, and bubble bath when washing, as these have an emulsifying effect on the lipids of the skin and can be damaging to the skin. Instead, a suitable soap substitute should be used, for instance an ointment dissolved in hot water (or lotion in warm water).</li><li>If large quantities (more than 100 g) of any paraffin-based product are used, they should regularly change clothing, bedding, or dressings which become impregnated with the product and keep away from naked flames, as they are highly flammable.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Eichenfield, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">MHRA, 2016</a>] </p><!-- end field b3877253-e2d1-4145-bb44-13ec56c07c15 --><!-- end item 9446f635-9143-4459-a7c1-4426d6601716 -->","subChapters":[]},{"id":"024bd4d4-38ef-59e2-b419-a052f7e4498c","slug":"quantity","fullItemName":"Quantity","depth":3,"htmlHeader":"<!-- begin field b7244e20-0db7-4cdd-b92f-39497f6820a8 --><h3>Quantity</h3><!-- end field b7244e20-0db7-4cdd-b92f-39497f6820a8 -->","summary":"","htmlStringContent":"<!-- begin item 7f124bb5-291a-4e36-89ad-85d0b5add0ef --><!-- begin field e7434a1b-525d-4c69-a4e1-2b2f1a030720 --><ul><li>Emollients are typically under-prescribed and under-used. This results in sub-optimal treatment of dry skin, and may increase the occurrence of flares.</li><li>Encourage appropriate usage by prescribing generous amounts (for example 500 g per week) to be used regularly (often four times daily).</li><li>Pump-dispensers should be prescribed when large quantities of cream or lotion are required, where possible. They are more convenient than other containers, and are less likely to become contaminated by potential pathogens.</li><li>The amount of emollient used should far exceed other topical treatments (for example corticosteroids) by a factor of at least ten.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2007</a>] </p><!-- end field e7434a1b-525d-4c69-a4e1-2b2f1a030720 --><!-- end item 7f124bb5-291a-4e36-89ad-85d0b5add0ef -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}